litlas
Log inCreate account

Takashi Seto

Active 1984–2024

98
Papers
23,388
Citations
57
h-index
98
i10-index

Citations

Citations per year for Takashi Seto1989: 1 citations1992: 1 citations1993: 2 citations1994: 2 citations1995: 3 citations1996: 4 citations1997: 2 citations1998: 4 citations1999: 8 citations2000: 2 citations2001: 3 citations2002: 5 citations2003: 2 citations2004: 3 citations2005: 5 citations2006: 6 citations2007: 18 citations2008: 16 citations2009: 26 citations2010: 47 citations2011: 84 citations2012: 83 citations2013: 143 citations2014: 166 citations2015: 256 citations2016: 194 citations2017: 183 citations2018: 215 citations2019: 683 citations2020: 946 citations2021: 1,074 citations2022: 884 citations2023: 615 citations2024: 928 citations2025: 369 citations2026: 19 citations1990–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,970 citing papers, 21.4% of this breakdownChina: 1,164 citing papers, 12.6% of this breakdownJapan: 798 citing papers, 8.7% of this breakdownItaly: 569 citing papers, 6.2% of this breakdownUnited Kingdom: 417 citing papers, 4.5% of this breakdownFrance: 414 citing papers, 4.5% of this breakdownSpain: 365 citing papers, 4% of this breakdownGermany: 358 citing papers, 3.9% of this breakdownSouth Korea: 326 citing papers, 3.5% of this breakdownCanada: 272 citing papers, 3% of this breakdownSwitzerland: 236 citing papers, 2.6% of this breakdownNetherlands: 229 citing papers, 2.5% of this breakdown
0%21.4%Other 22.6%

Institutions

Fields

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13.5%
  • Materials Science1.1%
  • Chemistry0.8%
  • Immunology and Microbiology0.8%
  • Computer Science0.5%
  • Other1.8%

Topics

  • Lung Cancer Treatments and Mutations20.4%
  • Lung Cancer Research Studies10.2%
  • Lung Cancer Diagnosis and Treatment6.8%
  • Cancer Genomics and Diagnostics5.4%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Colorectal Cancer Treatments and Studies2.8%
  • Other49.6%

Coauthors

All papers

Open in search
  1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Authors: Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorgé Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri - The Lancet Oncology 2019 cited by 1,744

  2. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    Authors: Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 cited by 997

  3. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 cited by 836

  4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Authors: Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka - The Lancet Oncology 2009 cited by 4,114

  5. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    Authors: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 cited by 3,406

  6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Authors: Benjamin Solomon, Benjamin Besse, Todd M. Bauer, Enriqueta Felip, Ross A. Soo, D. Ross Camidge, Rita Chiari, Alessandra Bearz, Chia‐Chi Lin, Shirish M. Gadgeel, Gregory J. Riely, Eng Huat Tan, Takashi Seto, Leonard P. James, Jill S. Clancy, Antonello Abbattista, Jean-François Martini, Joseph Chen, Gerson Peltz, Holger Thurm, Sai‐Hong Ignatius Ou, Alice T. Shaw - The Lancet Oncology 2018 cited by 789

  7. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

    Authors: George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo - Clinical Cancer Research 2022 cited by 209

  8. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz‐Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin‐Yuan Shih, Kwok Hung Au, Denis Moro‐Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt‐Moller, Carla Visseren‐Grul, Martin Reck, Quincy S. Chu, Alexis B. Cortot, Jean-Louis Pujol, Denis Moro‐Sibilot, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Reck, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan and 31 more - The Lancet Oncology 2019 cited by 613

  9. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Authors: Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R. Patel, Chao‐Hua Chiu, Thomas John, Kōichi Goto, Christos S. Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu Li, Young Kwang Chae, Christine H. Chung, Gregory A. Otterson, Haruyasu Murakami, Chia‐Chi Lin, Daniel Shao-Weng Tan, Hans Prenen, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele - The Lancet Oncology 2019 cited by 537

  10. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

    Authors: Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura - The Lancet 2017 cited by 912

  11. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

    Authors: Alexander Drilon, Chao‐Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lü, Myung‐Ju Ahn, Matthew Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S.W. Tan, Tejas Patil, Rafał Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena - JTO Clinical and Research Reports 2022 cited by 113

  12. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim, Shun Lü, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung‐Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Kemner Allison, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D. Wilner, Kōichi Goto - Journal of Clinical Oncology 2018 cited by 324

  13. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

    Authors: Takashi Seto, Terufumi Kato, Makoto Nishio, Kōichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Kosei Tajima, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto, Nobuyuki Yamamoto - The Lancet Oncology 2014 cited by 749

  14. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

    Authors: Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, Hideyuki Harada, Hiroshi Nokihara, Hideo Saka, Makoto Nishio, Hiroyasu Kaneda, Koichi Takayama, Osamu Ishimoto, Koji Takeda, Hiroshige Yoshioka, Motoko Tachihara, Hiroshi Sakai, Kōichi Goto, Nobuyuki Yamamoto - The Lancet Oncology 2017 cited by 533

  15. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

    Authors: Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Sun, Heather A. Wakelee, Russell W. Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai‐Hong Ignatius Ou - Clinical Cancer Research 2020 cited by 108

  16. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

    Authors: Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa - Journal for ImmunoTherapy of Cancer 2022 cited by 49

  17. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

    Authors: Nobuyuki Yamamoto, Takashi Seto, Makoto Nishio, Kōichi Goto, Nobuyuki Yamamoto, Isamu Okamoto, Takeharu Yamanaka, Masao Tanaka, Kosuke Takahashi, M. Fukuoka - Lung Cancer 2020 cited by 122

  18. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

    Authors: Jürgen Wolf, Maximilian J. Hochmair, Ji‐Youn Han, Noemı́ Reguart, Pierre‐Jean Souquet, Egbert F. Smit, Sergey Orlov, Johan Vansteenkiste, Makoto Nishio, Maja J.A. de Jonge, Wallace Akerley, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Takashi Seto, Garrett M. Frampton, Anna Robeva, Mariana Carbini, Sylvie Le Mouhaër, A. Yovine, Aislyn Boran, Claudia Bossen, Yiqun Yang, Lexiang Ji, Lauren Fairchild, Rebecca S. Heist - The Lancet Oncology 2024 cited by 64

  19. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

    Authors: Kazuhiko Nakagawa, Toyoaki Hida, Hiroshi Nokihara, Masahiro Morise, Koichi Azuma, Young Hak Kim, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Toru Kumagai, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Ryo Koyama, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Morihiko Hayashi, Wakako Hasegawa, Tomohide Tamura - Lung Cancer 2019 cited by 147

  20. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer

    Authors: Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, Katsuo Yoshiya, Toshiaki Takahashi, Tsuyoshi Ueno, Kōichi Goto, Haruko Daga, Norihiko Ikeda, Kenji Sugio, Takashi Seto, Shinichi Toyooka, Hiroshi Date, Tetsuya Mitsudomi, Isamu Okamoto, Kohei Yokoi, Hideo Saka, Hiroaki Okamoto, Yuichi Takiguchi, Masahiro Tsuboi - Journal of Clinical Oncology 2020 cited by 114

  21. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

    Authors: K. Park, Johan Vansteenkiste, Ki Hyeong Lee, G. Pentheroudakis, Caicun Zhou, Kumar Prabhash, Takashi Seto, P.J. Voon, Daniel S.W. Tan, James Chih‐Hsin Yang, J. Wang, K. Govind Babu, Yuko Nakayama, Adlinda Alip, Kevin Lee Min Chua, Jason Chia‐Hsien Cheng, Suresh Senan, Yong Chan Ahn, T.-Y. Kim, Hee Kyung Ahn, Solange Peters, Takayuki Yoshino, Jean-Yves Douillard - Annals of Oncology 2020 cited by 114

  22. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

    Authors: Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya, Shunsuke Teraoka, Yukari Tsubata, Hiroshige Yoshioka, Yoshihiro Hattori, Chiyo K. Imamura, Yuki Katsuya, Reiko Matsui, Yuji Minegishi, Hidenori Mizugaki, Kaname Nosaki, Yusuke Okuma, Setsuko Sakamoto, Takashi Sone, Kentaro Tanaka, Shigeki Umemura, Takeharu Yamanaka, Shinsuke Amano, Kazuo Hasegawa, Satoshi Morita, Kazuko Nakajima, Makoto Maemondo, Takashi Seto, Nobuyuki Yamamoto - International Journal of Clinical Oncology 2019 cited by 153

  23. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

    Authors: Katsuyuki Hotta, Toyoaki Hida, Hiroshi Nokihara, Masahiro Morise, Y.H. Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Toru Kumagai, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Takuya Yoshimoto, Souichi Takata Souichi Takata, Tomohide Tamura - ESMO Open 2022 cited by 77

  24. TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors

    Authors: Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, Chang‐Min Choi, Nong Yang, Geoffrey Liu, Enriqueta Felip, M. Pérol, Benjamin Besse, Jorgé Nieva, Luis E. Raez, Nathan A. Pennell, Anastasios Dimou, Filippo de Marinis, Fortunato Ciardiello, Takashi Seto, Zheyi Hu, Max Yu-Chen Pan, Weiqing Wang, Shuanglian Li, Sai‐Hong Ignatius Ou - Future Oncology 2023 cited by 31